

# USE OF FENSPIRIDE IN MAINTENANCE THERAPY OF STAGE II COPD PATIENTS

***Yu. I. Feshchenko, L. A. Yashyna, T. A. Pertseva,  
N. E. Monogarova, M. A. Polianskaya, S. G. Ishchuk,  
I. V. Jawad, L. A. Savelieva, A. V. Semendiaeva,  
E. V. Mironenko***

## *Summary*

COPD – is the disease of persistent inflammatory nature, leading to irreversible or partially reversible structural changes of airways and a numerous systemic effects. The beginning of the disease is slow, unnoticeable for the patient. But already by stage II the disease is characterized by fast decrease of pulmonary function indices. And it is not surprisingly that beginning from this stage it is recommended to administer continuous bronchodilator therapy. The aim of the study was to evaluate an effectiveness (influence on clinical symptoms, indices of pulmonary function, exercise capacity, disease associated quality of life) and tolerability of anti-inflammatory non-steroid medicine fenspiride in long-term (6 months) maintenance therapy (with combined short-acting bronchodilator) of stage II COPD patients.